July JAAD: Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE AD5)
AAD's Dialogues in Dermatology - Podcast autorstwa American Academy of Dermatology
George Han MD, FAAD interviewed by Elisa Gallo, MD, FAAD
